Uma Suganya Kuttalam Sambamoorthy, Govindaraju Kasivelu, Veena Vani Chitoor, Premanathan Mariappan, Ganesh Kumar Vijaya Kumar
Centre for Ocean Research, Sathyabama Institute of Science and Technology, Chennai-600 119, India.
Central Bioscience Research Laboratories (CBRL), Department of Biology, College of Science, Al-Zulfi, Majmaah University, Kingdom of Saudi Arabia.
IET Nanobiotechnol. 2019 Apr;13(2):226-229. doi: 10.1049/iet-nbt.2018.5139.
Diabetes mellitus has been considered as a heterogeneous metabolic disorder characterised by complete or relative impairment in the production of insulin by pancreatic β-cells or insulin resistance. In the present study, propanoic acid, an active biocomponent isolated from is employed for the synthesis of propanoic acid functionalised gold nanoparticles (Pa@AuNPs) and its anti-diabetic activity has been demonstrated in vitro. In vitro cytotoxicity of synthesised Pa@AuNPs was performed in L6 myotubes. The mode of action of Pa@AuNPs exhibiting anti-diabetic potential was validated by glucose uptake assay in the presence of Genistein (insulin receptor tyrosine kinase inhibitor) and Wortmannin (Phosphatidyl inositide kinase inhibitor). Pa@AuNPs exhibited significant glucose uptake in L6 myotubes with maximum uptake at 50 ng/ml. Assays were performed to study the potential of Pa@AuNPs in the inhibition of protein-tyrosine phosphatase 1B, α-glucosidases, and α-amylase activity.
糖尿病被认为是一种异质性代谢紊乱疾病，其特征是胰腺β细胞产生胰岛素完全或相对受损，或存在胰岛素抵抗。在本研究中，从[具体来源未给出]分离出的活性生物成分丙酸被用于合成丙酸功能化金纳米颗粒（Pa@AuNPs），并且其抗糖尿病活性已在体外得到证实。合成的Pa@AuNPs的体外细胞毒性在L6肌管中进行检测。通过在存在染料木黄酮（胰岛素受体酪氨酸激酶抑制剂）和渥曼青霉素（磷脂酰肌醇激酶抑制剂）的情况下进行葡萄糖摄取试验，验证了表现出抗糖尿病潜力的Pa@AuNPs的作用模式。Pa@AuNPs在L6肌管中表现出显著的葡萄糖摄取，在50 ng/ml时摄取量最大。进行了试验以研究Pa@AuNPs抑制蛋白酪氨酸磷酸酶1B、α-葡萄糖苷酶和α-淀粉酶活性的潜力。
